Clinical Research Directory
Browse clinical research sites, groups, and studies.
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Sponsor: Nanfang Hospital, Southern Medical University
Summary
The purpose of this study is to compare the efficacy and safety of venetoclax+decitabine+busulfan+fludarabine (VEN+DAC+Bu2Flu4) regimen with busulfan+fludarabine (Bu2Flu5) regimen in older patients with myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Official title: Venetoclax+Decitabine+Busulfan+Fludarabine (VEN+DAC+Bu2Flu4) vs Busulfan+Fludarabine Conditioning Regimen (Bu2Flu5 ) for Older Patients With Myeloid Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Key Details
Gender
All
Age Range
60 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2025-07-15
Completion Date
2029-12-31
Last Updated
2025-07-04
Healthy Volunteers
No
Conditions
Interventions
Venetoclax (VEN)
Venetoclax (VEN) was administered at 400mg/day on days -10 to -4.
Decitabine (DAC)
Decitabine (DAC) was administered at 20mg/m2/day on days -10 to -8.
Busulfan (Bu)
Busulfan (Bu) was administered at 3.2 mg/kg/day on days -5 to -4.
Fludarabine (Flu)
Fludarabine (Flu) was administered at 30mg/m2/day on days -5 to -2.
Fludarabine (Flu)
Fludarabine (Flu) was administered at 30mg/m2/day on days -6 to -2.